Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Lawrence A. Leiter
ResearcherPublications, citations & collaboration network
Lawrence A. Leiter is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 869 works, 92,495 citations, an h-index of 138 and an i10-index of 481.
869
Works
92,495
Citations
138
h-index
481
i10-index
How has Lawrence A. Leiter's publication output changed over time?
ScholarIQpublication output · 2012–2020
Output grew200% over the shown period — from 1 works in 2012 to 3 in 2020.
1
1
1
2
3
1
3
2012201320152016201820192020
What are the most-cited papers on Lawrence A. Leiter?
ScholarIQmost cited works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll
New England Journal of Medicine. 20166,751 CitationsOPEN ACCESS
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine
New England Journal of Medicine. 20186,387 CitationsOPEN ACCESS
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz
New England Journal of Medicine. 20133,486 CitationsOPEN ACCESS
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Jeffrey S. Riesmeyer, Matthew C. Riddle, Lars Rydén, Denis Xavier, Charles Atisso, Leanne Dyal, Stephanie Hall, Rao Ps, G.C. Wong, Álvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C. Cushman, Edward Franek, Nicolae Hâncu, M Hanefeld, Shaun Holt, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, Mercedes Abella, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, Maria Arzadun, María Antonietta Barbieri, Raúl Barcudi, Ines Bartolacci, Gabriel Bolobanich, Anselmo P. Bordonava, Miguel Bustamante Labarta, B. Bustos, Alberto Caccavo, Alejandra Camino, María del Rocío Cantero, Maria Carignano, Luis R Cartasegna, Marcela Cipullo, Víctor Commendatore, Victoria Conosciuto, Osvaldo Costamagna, Claudia A. Crespo, Jose Cuello, Carlos Alberto Cuneo, Sandra Cusimano, Sofia Dean, Claudio Fabián Dituro, Andrea Domínguez, Miguel Farah, Alberto Fernandez, Florencia Fernandez, Adriana Cristina Ferrari, Patricia Flammia, José Antonio Fuentealba, Karina Beatriz Gallardo, C. Perez Garcia, Ruben Garcia Duran, Marcelo Garrido, Rodolfo Gavícola, Claudio Gerbaudo, Graciela Gilli, Ana Paula Giotto, Pedro Godoy Bolzán, Oscar Gómez Vilamajó, Fernando Guerlloy, Cristian Guridi, Narcisa Gutierrez Garrido, Eduardo Hasbani, Sonia Hermida, Miguel Hominal, Adrian D. Hrabar, Adrián Ingaramo, Alejandra Izzicupo, Mario Krynski, Mariana Lagrutta, Paulina Virginia Lanchiotti, Maria Langhe, Veronica Leonard, Javier Llanos, Ricardo López Santi
The Lancet. 20193,109 CitationsOPEN ACCESS
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Remo H.M. Furtado, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine
The Lancet. 20182,848 Citations
Related on ScholarIQ
University of Toronto
Institution
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Paper
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Paper
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Paper
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Paper
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Paper